To the Editor The study by Cercek et al1 in JAMA Oncology was inspiring. It detailed a phase 2 single-arm study to evaluate and validate the efficacy and safety of combining hepatic arterial infusion (HAI) of floxuridine (14-day infusion, 4-week cycle) with systemic gemcitabine and oxaliplatin in patients (N = 38) with unresectable intrahepatic cholangiocarcinoma (IHC). The median progression-free survival (PFS) was 11.8 months (1-sided 90% CI, 11.1), and the overall survival (OS) was 25.0 months (95% CI, 20.6-not reached).1 Herein, we present several concerns about the study outcomes.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Yang X, Pan J, Zhao H. Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma. JAMA Oncol. 2020;6(6):935. doi:10.1001/jamaoncol.2020.0340
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: